Selloff Triggers Buy Debate: Social media buzz intensified after Synopsys shares plunged amid a broader software sector rout. Traders view the dip as a mischaracterization, emphasizing the company's pivotal role in electronic design automation for AI chips. Eyes are on February earnings for potential rebound catalysts.
AI Ecosystem Spotlight: Conversations highlight Synopsys' integration into massive hyperscaler capex plans powering next-gen silicon. Participants stress its tools enable complex chip designs for leaders like Nvidia and AMD. Ansys merger synergies are frequently cited as a key growth lever.
Oversold Opportunity: Oversold technicals prompt accumulation calls near support levels. Revenue projections nearing $10 billion underscore long-term strength in semiconductor complexity. Sentiment leans toward recovery as AI demand accelerates.
Note: This discussion summary was generated from an AI condensation of post data.
Synopsys Insider Trading Activity
Synopsys insiders have traded $SNPS stock on the open market 10 times in the past 6 months. Of those trades, 1 have been purchases and 9 have been sales.
Here’s a breakdown of recent trading of $SNPS stock by insiders over the last 6 months:
- SUDHINDRA KANKANWADI (Chief Accounting Officer) has made 0 purchases and 2 sales selling 15,873 shares for an estimated $7,837,408.
- SASSINE GHAZI (PRESIDENT AND CEO) sold 11,366 shares for an estimated $6,694,725
- SHELAGH GLASER (CFO) has made 0 purchases and 4 sales selling 7,312 shares for an estimated $3,913,745.
- JANET LEE (GC & Corporate Secretary) has made 0 purchases and 2 sales selling 500 shares for an estimated $260,000.
- ROBERT G PAINTER purchased 350 shares for an estimated $148,903
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
Synopsys Revenue
Synopsys had revenues of $2.3B in Q4 2025. This is an increase of 37.83% from the same period in the prior year.
You can track SNPS financials on Quiver Quantitative's SNPS stock page.
Synopsys Congressional Stock Trading
Members of Congress have traded $SNPS stock 5 times in the past 6 months. Of those trades, 2 have been purchases and 3 have been sales.
Here’s a breakdown of recent trading of $SNPS stock by members of Congress over the last 6 months:
- REPRESENTATIVE DAN NEWHOUSE purchased up to $15,000 on 12/31.
- REPRESENTATIVE GILBERT RAY CISNEROS, JR. has traded it 2 times. They made 0 purchases and 2 sales worth up to $30,000 on 11/18, 10/09.
- REPRESENTATIVE LISA C. MCCLAIN has traded it 2 times. They made 1 purchase worth up to $15,000 on 08/13 and 1 sale worth up to $15,000 on 09/11.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.
Synopsys Hedge Fund Activity
We have seen 716 institutional investors add shares of Synopsys stock to their portfolio, and 751 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- MORGAN STANLEY added 2,600,089 shares (+139.5%) to their portfolio in Q3 2025, for an estimated $1,282,857,911
- BLACKROCK, INC. added 2,371,463 shares (+18.5%) to their portfolio in Q3 2025, for an estimated $1,170,056,129
- PRICE T ROWE ASSOCIATES INC /MD/ removed 2,001,274 shares (-37.6%) from their portfolio in Q3 2025, for an estimated $987,408,578
- VICTORY CAPITAL MANAGEMENT INC added 1,990,608 shares (+238.8%) to their portfolio in Q3 2025, for an estimated $982,146,081
- FMR LLC added 1,868,243 shares (+47.5%) to their portfolio in Q3 2025, for an estimated $921,772,413
- COATUE MANAGEMENT LLC added 1,809,127 shares (+inf%) to their portfolio in Q3 2025, for an estimated $892,605,170
- UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC added 1,771,556 shares (+92.0%) to their portfolio in Q3 2025, for an estimated $874,068,014
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Synopsys Government Contracts
We have seen $473,464 of award payments to $SNPS over the last year.
Here are some of the awards which we have have seen pay out the most over the last year:
- TO RENEW CODE V/ETD: $112,238
- PURCHASE SOFTWARE FOR TCAD FABRICATION PROCESS SIMULATION: $110,100
- SYNPLIFY BASE PERPETUAL MAINTENANCE: $43,940
- SYNOPSYS SYNPLIFY SOFTWARE LICENSE: $33,800
- .1. THE PURPOSE OF ORDER W56JSR-23-P-0009 IS TO PROVIDE SUBSCRIPTION FIRM-FIXED-PRICE (FFP) SYNOPSIS SYNP...: $33,420
To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard.
Synopsys Analyst Ratings
Wall Street analysts have issued reports on $SNPS in the last several months. We have seen 11 firms issue buy ratings on the stock, and 1 firms issue sell ratings.
Here are some recent analyst ratings:
- B of A Securities issued a "Buy" rating on 12/11/2025
- Rosenblatt issued a "Buy" rating on 12/11/2025
- Citigroup issued a "Buy" rating on 11/24/2025
- Exane BNP Paribas issued a "Underperform" rating on 10/02/2025
- Morgan Stanley issued a "Overweight" rating on 09/11/2025
- Mizuho issued a "Outperform" rating on 09/11/2025
- Keybanc issued a "Overweight" rating on 09/10/2025
To track analyst ratings and price targets for Synopsys, check out Quiver Quantitative's $SNPS forecast page.
Synopsys Price Targets
Multiple analysts have issued price targets for $SNPS recently. We have seen 14 analysts offer price targets for $SNPS in the last 6 months, with a median target of $560.0.
Here are some recent targets:
- Clarke Jeffries from Piper Sandler set a target price of $520.0 on 01/13/2026
- Lee Simpson from Morgan Stanley set a target price of $550.0 on 12/12/2025
- Blair Abernethy from Rosenblatt set a target price of $560.0 on 12/11/2025
- Vivek Arya from B of A Securities set a target price of $560.0 on 12/11/2025
- Harlan Sur from JP Morgan set a target price of $650.0 on 12/11/2025
- Charles Shi from Needham set a target price of $580.0 on 12/11/2025
- Joe Quatrochi from Wells Fargo set a target price of $500.0 on 12/11/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
